Levamisole

Левамизол Drug photo

The description is actual on 10.05.2016

  • Latin name: Levamisole
  • ATH code: P02CE01
  • Active ingredient: Levamisole (Levamisole)
  • Producer: FC LLC Zdorovye (Ukraine)

Structure

1 tablet includes 150 mg of levamisole of a hydrochloride.

In addition: povidone, corn starch, stearic acid lactose.

Release form

The remedy Levamisole is made in the form of tablets No. 1 in the blister placed in a cardboard pack.

Pharmacological action

Anthelmintic (antivermicular).

Pharmacodynamics and pharmacokinetics

Derivative a thiazol imidazole levamisole belongs to group of the protivogelmintny medicines applied at nematodoses. This active ingredient is characterized by the fast anthelmintic efficiency which is shown thanks to its impact on gangliopodobny nematodny educations owing to what there is an oppression of the fumarating dehydrogenase, blocking of a succinatedehydrogenase and the depolarizing neuromuscular paralysis of a muscular membrane of helminths and, as a result, disturbance of biopower processes of helminths. The nematodes paralyzed thus are brought out of a human body thanks to a normal intestinal peristaltics at the act of defecation for 24 hours after oral administration of drug.

Absorption of levamisole at its internal reception comes from a digestive tract quickly enough. Achievement of plasma Cmax demands on average 90-120 minutes. Metabolic transformations of levamisole are carried out in a liver with allocation of key products of a metabolism – p-hydroxy-levamisole and its glucuronic derivative. T1/2 varies within 3-6 hours. Excretion of not changed drug from an organism happens less than for 5% to urine and less than for 0,2% to a stake.

Indications to use

As the protivogelmintny medical drug Levamisole is shown to appointment at ankilostomidoza, necatoriases and askaridoza.

Contraindications

Use of Levamisole is absolutely contraindicated to patients till 14 years, and also the patient with personal hypersensitivity to this drug.

Careful purpose of this remedy is demanded by patients with an oppressed marrowy hemopoiesis, pathologies of livers/kidneys, intolerance of sugars, and also pregnant women and the feeding women.

Side effects

In case of a single dose any negative effects of the carried-out treatment, as a rule, are not observed.

Occasionally against such therapy the short-term, not sharply expressed and independently passing undesirable phenomena including can be noted: nausea/vomiting, agranulocytosis, diarrhea, heartbeat, abdominal pains, leukopenia, headaches, spasms, sleeplessness, encephalopathy, dizziness. Also allow a possibility of forming of the reactions of hypersensitivity which are shown skin rashes and/or an itch and a Quincke's disease.

Application instruction of Levamisole

The tablet of drug is shown to be accepted orally (inside), it is the best of all during food or right after its reception in the evening and to wash down with the small volume of water.

The instruction recommends for Levamisole to the patients who reached 14 summer age, a single dose of the 1st tablet (150 mg). In case of need it is possible to carry out similar reception of a tablet after 7-14 days.

For the purpose of treatment of helminthoses at animals this dosage form of drug (tablet) is not appointed. For use in veterinary science the special 10% injection solution of levamisole are issued.

Overdose

In case of reception of levamisole in a dose more than 600 mg were noted intoxication phenomena which are characterized: dizziness, nausea/vomiting, spasms, diarrhea, confusion of consciousness, headaches, spasms and possibly lethargy.

For therapy of similar states carrying out cleaning of a gastrointestinal tract (an enema, a gastric lavage) and a symptomatic treatment under a constant control of the vital indicators is shown. At identification of the antikholinesterazny action connected with overdose recommend administration of atropine.

Interaction

At the combined use increase in plasma concentration of Phenytoinum and respectively strengthening of its efficiency is observed.

Parallel reception with coumarinic anticoagulants can lead to lengthening of a prothrombin time that demands careful selection of dosages of anticoagulants.

Co-administration with lipophilic means (ether, phenoxin, henopodiya oil, tetrachlorethylene, chloroform) can become the toxicity strengthening reason.

Terms of sale

It is possible to buy Levamisole without existence of the recipe.

Storage conditions

The maximum surrounding air temperature for storage of tablets in original packaging makes 25 °C.

Period of validity

3 years of date of production.

Special instructions

One-time reception of a tablet does not demand observance of a diet or reception of purgatives.

Because of inclusion in structure of a remedy of lactose, its appointment to patients with intolerance of sugars demands extra care.

It is also carefully necessary to accept drug the patient with pathologies of livers/kidneys, cerebrovascular disturbances and an oppressed hemopoiesis.

For 24 hours after reception of a tablet it is forbidden to use etanolsoderzhashchy means / drinks.

Analogs

Coincidence on the ATH code of the 4th level:

Analogs of a remedy of Levamizol-Zdorovye, on its active ingredient, are provided by drugs: Decarice and Levamisole (Elegant India).

Apteka24

  • Levamisole of 7.5% 50mlolkar (Ukraine)
  • Levamizolzdorovye (Ukraine, Kharkiv)

Paniapteka

  • Levamisole of / x tab. of 150 mg No. 1
Section: Antiparasitic
in more detail

Education: Graduated from the Vinnytsia national medical university of N. I. Pirogov, pharmaceutical faculty, the higher pharmaceutical education – the specialty "Pharmacist".

Experience: Work in Koneks and Bios-Media pharmacy chains as "Druggist". Work as "Pharmacist" in Avicenna pharmacy chain of the city of Vinnytsia.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Levamisole surely consult with the attending physician.